Followers | 170 |
Posts | 8965 |
Boards Moderated | 0 |
Alias Born | 01/24/2011 |
Monday, October 02, 2017 1:52:38 PM
I emailed HEMP's Transfer Agent every few weeks to check the up-to-date, current OS, and did so again today.
As of the morning of October 2, 2017, HEMP's OS is now 2,481,722,897 shares, which is an increase of 443.4MM shares (+21.8%) from the end of 3Q/17. Since September 12, 2017, the date of my most recent previous call, 75.3M shares were added.
There have been 63 workdays since the end of 3Q/17. Over that period, Perlowin has increased the OS by an average of 7.0M shares/workday, which is a fantastic rate of dilution.
Here are the dates of my calls and amounts of shares reported for each:
Call Date - Outstanding Shares
12/31/16 - 1,232,057,331
1/9/2017 - 1,362,522,331
1/18/2017 - 1,432,410,664
1/27/2017 - 1,490,469,956
2/16/2017 - 1,619,268,575
3/8/2017 - 1,717,198,663
3/31/2017 - 1,748,651,127 <-- Same as reported by Hemp on 5/22/17 in the 1Q/17 filing
4/6/2017 - 1,772,216,171
4/20/2017 - 1,797,216,171
5/1/2017 - 1,814,915,286
5/18/2017 - 1,844,915,286
6/6/2017 - 1,957,306,688
7/3/2017 - 2,038,306,688 <-- Same as reported by Hemp on 8/11/17 in the 2Q/17 filing
7/28/2017 - 2,091,676,634
8/4/2017 - 2,190,597,957
9/12/2017 - 2,406,424,456
10/2/2017 - 2,481,722,897 <-- Should be close to what HEMP will report in its 3Q/17 filing
In my previous OS Report, I said that I thought that the OS would exceed 2.5B shares by the end of the third quarter, but that forecst was high by about 18.5M shares. Still, my estimate was only about 0.75% higher than the actual number reported by the TA.
Nearly 1.25B shares have been issued since Dec 31, 2016, a 101.4% increase! HEMP's OS has doubled in nine months, while the company has not generated any significant revenue over the same period.
"Soylent Green is people!!!"
Detective Robert Thorn: Telling uncomfortable truths since 2022
DRT is Charleton Heston's character in the 1973 movie, Soylent Green, set in the year 2022, and is not my real name
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM